Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Helena Doktorova, Jan Hrabeta, Mohamed Ashraf Khalil, Tomas Eckschlager

Background. The aim of this review is to provide the information about molecular basis of hypoxia-induced chemoresistance, focusing on the possibility of diagnostic and therapeutic use.

Results. Hypoxia is a common feature of tumors and represents an independent prognostic factor in many cancers. It is the result of imbalances in the intake and consumption of oxygen caused by abnormal vessels in the tumor and the rapid proliferation of cancer cells. Hypoxia-induced resistance to cisplatin, doxorubicin, etoposide, melphalan, 5-fluorouracil, gemcitabine, and docetaxel has been reported in a number of experiments. Adaptation of tumor cells to hypoxia has important biological effects. The most studied factor responsible for these effects is hypoxia-inducible factor-1 (HIF-1) that significantly contributes to the aggressiveness and chemoresistance of different tumors. The HIF-1 complex, induced by hypoxia, binds to target genes, thereby increasing the expression of many genes. In addition, the expression of hundreds of genes can be also decreased in response to hypoxia in HIF-1 dependent manner, but without the detection of HIF-1 in these genes' promoters. HIF-1 independent mechanisms for drug resistance in hypoxia have been described, however, they are still rarely reported. The first clinical studies focusing on diagnosis of hypoxia and on inhibition of hypoxia-induced changes in cancer cells are starting to yield results.

Conclusions. The adaptation to hypoxia requires many genetic and biochemical responses that regulate one another. Hypoxia-induced resistance is a very complex field and we still know very little about it. Different approaches to circumvent hypoxia in tumors are under development.

Key words: HIF-1, hypoxia, chemoresistance, hypoxia-induced chemoresistance

INTRODUCTION – HYPOXIA-INDUCED CHEMoresistance

Hypoxia is a common feature of a solid tumor’s microenvironment and represents an independent prognostic factor for a variety of human cancers. For the purposes of this paper, references to tumor hypoxia can refer to the tumor as a whole or any part thereof in which hypoxia create a microenvironment. It is the result of imbalances in the intake and consumption of oxygen. This results from vascularization that is structurally and functionally abnormal, coupled with high proliferation rates in tumor cells1.

The negative impact of hypoxia on cancer cells relates to the efficacy of radio- and chemotherapy has been known for several decades and the survival rate of patients with severely hypoxic tumors is shorter than patients with less hypoxic tumors2. In radiotherapy, low oxygen levels prevent the formation of DNA strand breaks induced by radiation, and inhibits repair of DNA damage that induces genetic instability3,4. Hypoxia-induced resistance to cisplatin, doxorubicin, etoposide, melphalan, 5-fluorouracil, gemcitabine, and docetaxel has been previously reported in a number of tumor cell types5–23.

Hypoxia regulates approximately 1% of the genes that play a role in the signaling pathways that control various aspects of tumor progression24. Adaptation of tumor cells to hypoxic conditions has important biological effects and contributes to the aggressive nature of tumors and their dedifferentiation and chemoresistance. In this context, the most studied transcription factor is hypoxia-inducible factor-1 (HIF-1). HIF-1 is an important factor in the adaptation of cells to hypoxic environments, and significantly contributes to the aggressiveness and chemoresistance of number of different tumors5,7–9,15,19,21,25–30. However, these changes can be independent of HIF-1 (ref.26,31). In several cell types, hypoxia-induced drug resistance is unaffected or only partially reversed by HIF-1 inhibition, suggesting the existence of HIF-1 independent mechanisms of hypoxia-induced drug resistance. Other reasons for chemoresistance of cells in hypoxic tumors include acidosis, nutrient starvation that inhibits cell proliferation, increased interstitial fluid pressure, and low drug concentrations. Tumors that are hypoxic because of abnormal vascularization also have decreased drug bioavailability32. Therefore, inadequate pharmacokinetics in these areas may reduce the effectiveness of anticancer drugs even though they are effective under hypoxic conditions or even inhibit HIF-1α. Furthermore, HIF-1 knockdown cells can normally grow and survive in hypoxic conditions33. HIF-1 independent mechanisms of drug resistance in hypoxia are under investigation, but are still rarely reported.

The aim of this review is to provide general information about the molecular basis of hypoxia-induced chemoresistance.
resistance, focusing on diagnostic and therapeutic uses in clinical oncology.

THE ROLE OF HIF-1

HIF-1 is a master regulator of oxygen homeostasis with pleiotropic effects. It is a heterodimeric transcription factor composed of 2 subunits – an oxygen-regulated subunit HIF-1α and a stable constitutively expressed nuclear factor, HIF-1β (aryl hydrocarbon receptor nuclear translocator, ARNT). Each subunit contains bHLH-PAS domains that mediate heterodimerization and DNA binding. Under normoxic conditions HIF-1α is hydroxylated by prolyl hydroxylase (PHD) at prolines 402 and 564, and hydroxylated HIF-1α recruits von Hippel-Lindau protein (pVHL), an E3 ubiquitin protein ligase, and is degraded by the 26S proteasome after being targeted for ubiquitination. Recently, an additional mechanism has been recognized (by which HIF-1α is degraded in lysosomes via chaperone mediated autophagy, including HSC70 and LAMP2A) that is independent of proteasome activity.

Under hypoxic conditions, cytosolic HIF-1α is stabilized by inhibition of PHD-dependent enzymatic hydroxylation of proline residues and subsequently is translocated to the nucleus, where it binds to HIF-1β (ref.34-36). The HIF-1 complex then binds to the hypoxia-response element (HRE) of the target genes (Fig. 1) (ref.35), which causes increased expression of hundreds of genes (Table 1) (ref.34). In addition, the expression of many other genes is decreased in response to hypoxia (in a HIF-1 dependent manner), but without the detection of HIF-1 in the gene promotors. Moreover, tumor hypoxia (in a HIF-1 dependent manner) may upregulate receptor tyrosine kinases.

Table 1. Classification of HIF-1 regulated genes (modified according to ref.42,43).

<table>
<thead>
<tr>
<th>Biological functions</th>
<th>Gene symbol/alias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription factors</td>
<td>TWIST1, Snail, ZEB1, ZEB2, ID2, SMAD7, PPARγ, GATA1</td>
</tr>
<tr>
<td>Histone modifiers</td>
<td>JMJD2B, JMJD2C, MLL1</td>
</tr>
<tr>
<td>Enzymes</td>
<td>MMP1, MMP3, LOX, ADAMTS1, ACE, ACE2, XPA, HK1, HK2</td>
</tr>
<tr>
<td>Receptors, receptor-associated kinase</td>
<td>CXCR4, CX3CR1, uPAR, PAI-1, 67-kDa laminin receptor, c-Met</td>
</tr>
<tr>
<td>Small GTPases, intracellular signaling molecules</td>
<td>VEGF, TGF-α, TGF-β3, IGF2, Cdc42, Rac1, RhoE, IRS-2</td>
</tr>
<tr>
<td>Transporters</td>
<td>glut-1, glut-3, MDR1, VDAC1, transferrin, ceruloplasmin, IGF-BP1 - 3</td>
</tr>
<tr>
<td>Membrane proteins</td>
<td>ANGPTL4, L1CAM, α5 integrin, CD151, CD24, CD147, Galectin-1 and 3, MUC1, Semaphorin 4D, Caveolin-1</td>
</tr>
<tr>
<td>Scaffold protein, cytoplasmic protein</td>
<td>HEF1, Lipirin-α4</td>
</tr>
<tr>
<td>Matricellular proteins</td>
<td>CYR61, NOV</td>
</tr>
</tbody>
</table>
including EGFR, through the repression of rabaptin-5 transcription\(^6\). Many effects of HIF-1 are therefore made at the level of gene transcription; however, the direct interactions of HIF-1 with other proteins, e.g. interaction between HIF-1α and c-myc or p53, remain very important\(^46\).

During hypoxia, the pVHL-dependent proteasomal degradation of HIF-1α does not occur. Thus, HIF-1α is stabilized and transported to the nucleus where it forms a transcriptional complex with the ARNT/HIF-1β subunit. In the presence of transcriptional coactivators (not shown) HIF-1 complex can cause transcriptional activation of the target genes leading to cell adaptation to hypoxic conditions.

Besides HIF-1α, there are two other transcription factors in this family of proteins, HIF-2α and HIF-3α. The regulation and function of HIF-3α is not yet entirely clear; it is the least-studied protein of these factors\(^44\). HIF-2α, also known as EPAS1 (Endothelial PAS domain-containing protein 1) is highly homologous to HIF-1α, i.e., they share very similar protein structure and the mechanism of their stabilization and action are also very similar\(^45\). Despite the similarities, HIF-2α has several different transcriptional targets than HIF-1α, which can also be activated during severe hypoxia\(^46\). HIF-2α can be detected at near physiological pO2 and its expression is tissue specific. Neuroblastoma cells in contact with blood vessels, and stromal cells surrounding the tumor have been shown to be HIF-2α positive\(^47\). Overexpression of HIF-2α is also observed in hemangioblastoma cells, which are very rich in blood vessels\(^48\). One specific HIF-2α target gene is Oct-4, which encodes a transcription factor essential for the pluripotency of stem cells. Its activation is responsible for tumor cell dedifferentiation that has been demonstrated in neuroblastomas, breast cancer, and is probably the same in other tumours\(^49,50\). Activation of the Notch signaling pathway also participates in the loss of cell differentiation\(^52,53\).

Moreover, HIF-1 regulates several miRNAs while other miRNAs target HIF-1. Changes in miRNA expression, in response to hypoxia, are shown in Table 2. The interaction between miRNAs and HIF-1 may influence many signaling pathways important for angiogenesis, metabolism, apoptosis, cell cycle regulation, proliferation, metastasis, and resistance to anticancer therapy\(^54\).

**HIF-1 AND CHMORESISTANCE**

The association of HIF-1α overexpression with cell proliferation and poor prognosis has been observed in many human cancers\(^25,36,55\). Many of these HIF-1 inducible genes such as VEGF, Glut-1, MDR, and Bcl-2 directly or indirectly mediate chemoresistance\(^56\). Therefore, in a wide range of different tumor types, e.g. hepatocellular carcinoma, neuroblastoma, and lung cancer, inhibition of HIF-1α resensitizes cells to drug treatment in hypoxia and is then a valid target to reverse hypoxia-induced drug resistance\(^8,9,15,19,21,25,27-30,54\). HIF-1α accumulation has been associated with shorter survival in patients with early stage cervical, breast, ovarian, endometrial, oropharyngeal squamous cell carcinoma, and oligodendroglioma. Significant associations between HIF-2α overexpression and increased patient mortality have been reported for other diseases, including non-small-cell lung cancer (NSCLC), neuroblastoma, astrocytoma, and head and neck squamous cell carcinoma\(^7\).

Hypoxia-induced drug resistance in tumors has been reported for vincristine, doxorubicin, cisplatin, etoposide in neuroblastoma cells\(^15,59\); doxorubicin, vincristine, and actinomycin-D in rhabdomyosarcoma and Ewing’s sarcoma cells\(^15,26\); cisplatin, doxorubicin, and etoposide in osteosarcoma\(^46\); 5-fluorouracil, paclitaxel, doxorubicin, gemcitabine, and cisplatin in head and neck squamous cell carcinoma\(^61,62\); 5-fluorouracil and cisplatin in gastric cancer\(^65\); cisplatin and doxorubicin in NSCLC (ref.\(^8\)); and doxorubicin, etoposide, vincristine, and methotrexate in acute lymphoblastic leukemia\(^64\). The data came mainly from *in vitro* studies. Known HIF-1 transcriptional tar-

**Table 2.** Examples of changes of miRNAs expression in response to hypoxia (adapted according to ref.\(^54\)). miRNAs can be up-regulated as well as down-regulated, which reflects the complexity of miRNA in hypoxia regulation.

<table>
<thead>
<tr>
<th>Up-regulated miRNAs</th>
<th>The details of regulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-10b, miR-372/miR-373</td>
<td>regulated by HIF-1α (via TWIST)</td>
</tr>
<tr>
<td>miR-103/miR-107</td>
<td>repress DAPK and KLF4 (role in metastasis)</td>
</tr>
<tr>
<td>miR-155</td>
<td>regulated by HIF-1α, can also negatively influence the stability and activity of HIF-1α</td>
</tr>
<tr>
<td>miR-21</td>
<td>regulated by Akt2 (via NF-kB and CREB) or RAS/ERK signaling, activate Akt and ERK1/2 pathways leading to the elevation of HIF-1α and VEGF (via targeting PTEN)</td>
</tr>
<tr>
<td>miR-210</td>
<td>stabilize HIF-1α (via GPD1L repression), inhibit the expression of E2F3 and MNT (control cell cycle progression), down-regulates VMP1</td>
</tr>
<tr>
<td>miR-424</td>
<td>suppresses CUL2 (can stabilize HIF-1α)</td>
</tr>
<tr>
<td>miR-519c</td>
<td>regulates HIF-1α (angiogenesis)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Down-regulated miRNAs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-17-92</td>
<td>regulated by wild-type p53, stabilize HIF-1α</td>
</tr>
<tr>
<td>miR-107</td>
<td>reduce the inhibition of HIF-1β (promotes angiogenesis)</td>
</tr>
<tr>
<td>miR-20b, miR-200b</td>
<td>regulated by HIF-1α</td>
</tr>
<tr>
<td>miR-20b, miR-199</td>
<td>stabilize HIF-1α</td>
</tr>
</tbody>
</table>
gets may induce drug resistance by affecting drug trans-
porters, e.g. increased p-glycoprotein (MDR1, multidrug
resistance 1) (ref.65); drug targets, e.g. decreased topoi-
somerase II (ref.25); or by changing the response to drugs,
for instance by modifying drug-induced apoptosis58, reduc-
ning drug induced senescence 9, or inducing autophagy in
response to drugs (Table 3) (ref.27). It has been shown that
HIF-1 inhibition reverses multidrug resistance in colon
cancer66 and HIF-1α knockout cells are more sensitive to
cytostatics and irradiation than wild-types32.

HIF-1 AS A PRO-OR ANTIAPOPTOTIC FACTOR

Besides the protective responses, HIF-1 and/or hy-
poxia have also been shown to be either anti-apoptotic or
proapoptotic, based on cell type and severity of hypoxia.
More severe or prolonged hypoxia induces apoptosis that
is, at least in part, initiated by the direct association of
HIF-1α and p53 (ref.67,68). Among proapoptotic genes
regulated by HIF-1 are p53 (whose relation to HIF-1 is,
however, very complicated and often seems to be contro-
versial) and genes belonging to the Bcl-2 family of pro-
teins – BNIP3, NIX and NOXA (ref.69,70).

BNIP3 (Bcl-2/adenovirus E1B 19 kDa interacting
protein 3) is expressed in the brain and skeletal muscles
under normal conditions71, but its function is unknown.
In most other tissues, BNIP3 expression is induced by
HIF-1 under hypoxic conditions. BNIP3 has also been
shown to induce cell type specific necrosis, apoptosis,
and autophagy72,67. Proapoptotic functions of BNIP3 have
been well documented in cardiomyocytes. On the other
hand, while BNIP3 is expressed in hypoxic regions of
tumors it fails to induce cell death. In ovarian cancer,
the overexpression of BNIP3 truncated forms with muta-
tions in bcl2-binding domain fail to induce cell death.
Furthermore, the BNIP3 proapoptotic effect can be cir-
sumvented by EGFR signaling in epithelial cancer cells.
Therefore, whether hypoxia-induced BNIP3 has a pro-
or anti-apoptotic effect depends on the context and upon
what genetic changes the cancer cells experience. From
this point of view, hypoxia creates a strong selective pres-
sure and selects cells with survival advantages and cell
death resistance. Pro-apoptotic transcription factor p53 is
considered to be the most common inhibitor of cellular
proliferation as well as inducer of apoptosis. When cells
sense a decrease in oxygen, HIF-1 can enhance the stabil-
ity of p53 and these two transcription factors cooperate
with each other to induce apoptosis that is p53-HIF-1-de-
pendent68. The direct interaction between p53 and HIF-1α
results in not only p53 stabilization but also inhibition of
HIF-1-dependent transcription. This effect may explain
the competition between p53 and HIF-1 for the p300
coactivator as well as MDM2 dependent degradation of
HIF-1α via formation of the p53/HIF-1/MDM2 complex
(ref.73,74). However, the precise relationship of HIF-1 and
p53 is still very complicated and unclear. The interaction
between HIF-1 and p53 has been previously and com-
prehensively reviewed75. Based on the above-mentioned
information, apoptosis or cell survival in hypoxic regions
of tumors probably depends on the type of tumor and the
presence or absence of genetic alterations that affect the
balance between pro-apoptotic and anti-apoptotic roles of
hypoxia-induced factors76.

### Table 3. Overview of HIF-1 mediated drug resistance mechanisms (modified according to ref.32).

<table>
<thead>
<tr>
<th>Cancer cell model</th>
<th>Drug/molecule</th>
<th>Resistance phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>etoposide</td>
<td>DNA damage inhibition</td>
</tr>
<tr>
<td></td>
<td>methotrexate</td>
<td>drug efflux</td>
</tr>
<tr>
<td></td>
<td>paclitaxel, doxetaxel</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>adriamycin</td>
<td>drug efflux</td>
</tr>
<tr>
<td></td>
<td>etoposide, oxaliplatin</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>Fibrosarcoma</td>
<td>cisplatin, etoposide</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>multiple drugs</td>
<td>drug efflux</td>
</tr>
<tr>
<td></td>
<td>5-fluoruracil</td>
<td>apoptosis inhibition; senescence inhibition</td>
</tr>
<tr>
<td>Glioblastoma</td>
<td>adriamycin</td>
<td>drug efflux</td>
</tr>
<tr>
<td>Gliona</td>
<td>etoposide, doxorubicin</td>
<td>drug efflux</td>
</tr>
<tr>
<td>HCC</td>
<td>5-fluoruracil</td>
<td>drug efflux</td>
</tr>
<tr>
<td></td>
<td>etoposide</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>HeLa cells</td>
<td>4-HPR</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>HNSCC</td>
<td>paclitaxel</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>etoposide, vincristine</td>
<td>apoptosis inhibition</td>
</tr>
<tr>
<td>OSCC</td>
<td>5-fluoruracil, cisplatin</td>
<td>drug efflux; ROS decrease</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>etoposide</td>
<td>DNA damage inhibition</td>
</tr>
<tr>
<td></td>
<td>flutamide</td>
<td>apoptosis inhibition</td>
</tr>
</tbody>
</table>
OTHER FACTORS RESPONSIBLE FOR HYPOXIA-INDUCED CHEMORESISTANCE

Other factors besides HIF-1 must be responsible for the cellular response to hypoxia and hypoxia-induced chemoresistance. A number of other cellular pathways are differentially regulated in hypoxia and may also contribute to hypoxia-induced drug resistance. It has been shown that the suppression of HIF-1α through gene knockdown or the use of small molecule inhibitors reduces resistance to cytostatics, such as cisplatin, etoposide, doxorubicin, and ellipticine, but does not suppress it completely. The fact that in some cell lines (e.g. neuroblastoma, osteosarcoma, and lung adenocarcinoma) chemoresistance persists or is only partially reversed, despite HIF-1 being eliminated, points to alternative hypoxia-induced survival pathways.

Hypoxia selects more resistant cells having aggressive and metastatic phenotypes, which are often associated with poor prognoses, e.g., prostate cancer cells. This resistance to hypoxia-induced apoptosis may be due to the increased expression of anti-apoptotic factors including the IAP3 and Bcl-2 family of proteins and is independent on HIF-1. Inhibition of the phosphoinositol-3-kinase (PI3K) pathway, nuclear factor kappa-B (NF-κB), cyclooxygenase-2 (COX-2), activator protein-1 (AP-1), c-jun, Pim-1, and STAT-3 can reverse resistance to cytostatics in hypoxia, implying a role for these pathways in hypoxia-induced drug resistance. However, the degree in which they are dependent on functional HIF-1 is uncertain.

Nuclear factor-κB (NF-κB) is a ubiquitous transcription factor that is composed mainly of homo- or heterodimers of p50 and p65. NF-κB has been found to be overexpressed in tumors and to be activated by hypoxia. Whether hypoxia-induced NF-κB activation contributes to tumor cell resistance or sensitivity to chemotherapy is still unknown. The contribution of NF-κB to chemoresistance has been reported in many cancers. Under resting conditions, NF-κB is held inactive in the cytoplasm, bound to NF-κB inhibitors (IκBα, IκBβ, IκBγ, and IκBe) (ref.87). Upon stimulation with different substances, such as tumor necrosis factor alpha (TNF-α), IκBs are ubiquitinated and degraded and NF-κB is released and translocated to the nucleus (ref.88,89). NF-κB then activates the transcription of target genes involved in angiogenesis, cell proliferation, and survival (ref.90). NF-κB up-regulates the expression of anti-apoptotic genes such as Bcl-2 (ref.91), cellular inhibitors of apoptosis (c-IAPs), and Bcl-XL (ref.92,93). However, other reports have suggested that NF-κB could also function as a tumor suppressor and the inhibition of its activity could counteract the effects of chemotherapy (ref.94,95). Moreover, NF-κB subunits p50 and p65 have been shown to directly interact with HIF-1, during hypoxia, at a distinct element in the proximal promoter of the HIF-1α gene (ref.96,97), and these two transcription factors appear to share common regulatory pathways. However, other reports have suggested that NF-κB could also function as a tumor suppressor and the inhibition of its activity could counteract the effects of chemotherapy (ref.94,95). Moreover, NF-κB subunits p50 and p65 have been shown to directly interact with HIF-1, during hypoxia, at a distinct element in the proximal promoter of the HIF-1α gene (ref.96,97), and these two transcription factors appear to share common regulatory pathways. Hypoxia may stop suppression of NF-κB activity through decreased PHD-dependent hydroxylation of IKKβ (IκB kinase sub-unit beta) (ref.98). All the observations, taken together, leave no doubt that the cross-talk between NF-κB and HIF-1 is of an importance in the treatment of cancer.

Cyclooxygenase-2 (COX-2) and sphingosine kinase 2 (SphK2). It is thought that COX-2 inhibitors prevent the development of resistance to different cytostatics and that COX-2 overexpression induces increased multidrug resistance protein 1 (MRP1) expression in different cancer cells (ref.99,100). Schneider et al. showed that COX-2 is up-regulated under hypoxia in a HIF-1α-independent fashion and sphingosine-1-phosphate (S1P) is responsible for COX-2 induction under hypoxia in A549 lung cancer cells (ref.101). Simultaneous inhibition of HIF-1 and COX-2 strongly suppresses chemoresistance and the inhibition of only COX-2 decreases chemoresistance of cancer cells in hypoxia (ref.102). S1P formation and release are promoted by SphK2 expression, which is also responsible for enhancing its activity. Most likely, hypoxia causes an increase in SphK2 by achieving post-translational protein modification. However, the enhancing of mRNA transcription and translation or affecting mRNA stability is also possible (ref.103–106). The extracellular S1P activity leads to chemoresistance mediated via S1P1/S1P3 receptors and p42/44 MAPK-dependent signaling pathways as well (ref.106).

Protein survival kinases PI3K and Akt. Phosphatidylinositol-3 kinases (PI3K) phosphorylate inositol phospholipids, generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) on the inner surface of the plasma membrane. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) interacts with these phospholipids, causing its translocation to the inner membrane where it is phosphorylated and activated by pyruvate dehydrogenase kinases 1 and 2 (PDK1 and PDK2). Activated Akt modulates the function of numerous substrates involved in the regulation of cell survival, cell cycles, and cell growth (ref.107). The PI3K/Akt signaling pathway is frequently affected in human cancers, which can induce angiogenesis and oncogenic transition, both in a HIF-1α-dependent and -independent manner. Activation of PI3K and Akt protect cells against apoptosis and induces drug resistance during both normoxia and hypoxia. PI3K/Akt inhibition is able to reverse this resistance (ref.108). In pancreatic cancer, hypoxia-induced resistance to gemcitabine was shown to be also partially dependent on the MAPK (Erk) signaling pathway and NF-κB (see above). Therefore, a combination of tyrosine kinase inhibitor with gemcitabine should be an effective therapy for pancreatic cancer. It has been shown that hypoxia increases phosphorylation of Akt (ref.109), but still, similar to other signals, the mechanism of hypoxia-mediated PI3K/Akt-dependent chemoresistance has not been laid out in detail.

Signal transducer and activator of transcription 3 (STAT3). It has been shown that enhanced glycolysis in hypoxic tumor cells is dependent on HIF-1α up-regulation, while reduced mitochondrial activity is HIF-1α-independent and likely caused by STAT3-mediated down-regulation of mitochondrial proteins. Constitutively active pro-oncogenic transcription factor STAT3 acts as a regulator of cell metabolism, inducing aerobic glycolysis and down-regulating mitochondrial activity, both in primary fibroblasts and in STAT3-dependent tumor cell...
lines. As a result, cells are protected from apoptosis and senescence while becoming highly sensitive to glucose deprivation\textsuperscript{108}. STAT3 activation is significantly increased by the tumor hypoxia and is accompanied by increased ROS generation\textsuperscript{123}. Moreover, STAT3 directly regulates both cell proliferation and pro-survival genes, both of which provide growth advantages to tumor cells by blocking pro-apoptotic genes\textsuperscript{23,109}. Pharmacological inhibitors of STAT3 have been shown to significantly reduce cell proliferation capacity under hypoxic conditions and induce apoptosis in a variety of human cancer cells, e.g. breast, prostate, colon, and ovarian cancers\textsuperscript{110–112}. Also, STAT3 inhibition partially overcame hypoxia-induced chemoresistance to cisplatin and taxol treatment\textsuperscript{23,112}. Therefore, it seems that STAT3 activation might contribute to cellular resistance to anticancer drug-induced apoptosis. However, how STAT3 is activated in hypoxic cancer cells remains an intriguing question and it is obvious that STAT3 can act both HIF-1α dependently or independently. It is reported that the VEGF promoter contains various transcription factor binding sites including STAT3 (ref.\textsuperscript{113}) and HIF-1 (ref.\textsuperscript{114}). In hypoxia, STAT3 can interact with HIF-1α, increase its levels\textsuperscript{109} while both transcription factors control VEGF transcriptional activation leading to maximum activity and angiogenesis. Therefore, targeting STAT3/HIF-1α/VEGF signaling can be a potent anti-angiogenic strategy in tumors\textsuperscript{15,116}.

Pim kinases. The Pim serine/threonine kinases Pim-1, Pim-2, and Pim-3 regulate signaling pathways that contribute to tumor cell proliferation, expression of survival proteins and drug efflux transporters, and inhibit apoptosis. They affect tumor cell proliferation and survival through multiple mechanisms that include inhibition of major signaling pathways, interference with the activity of specific cell cycle molecules, and changes in gene expression\textsuperscript{117}. Overexpression of Pim kinases has been observed in patients with non-Hodgkin’s lymphoma, leukemia, and prostate cancer\textsuperscript{118–121}. The up-regulation of Pim kinases by hypoxia appears to be limited to Pim-1 (ref.\textsuperscript{117}) and is HIF-1α independent\textsuperscript{118}. Hypoxia-induced expression of Pim-1 is associated with metastasis and worse treatment response, while inhibition of Pim-1 suppresses cell proliferation and migration, induces apoptosis, and increases sensitivity to cytotoxic drugs, e.g. to cisplatin, doxorubicin, and gemcitabine in pancreatic carcinoma\textsuperscript{18} or to docetaxel in prostate cancer cells\textsuperscript{122,123}; this was found to be true under hypoxic conditions both in vitro and in vivo\textsuperscript{118,117}. The Pim-1 expression level also correlates with tumor prognosis\textsuperscript{118}.

Pim-1 induces resistance to anticancer drugs through stabilization of the mitochondriad transmembrane potential and regulates apoptosis, the cell cycle, and gene transcription by phosphorylating target proteins such as Bad, p21/waf1, c-Myb, and c-Myc (ref.\textsuperscript{18,125–129}). Pim-1 down-regulates p27(Kip1) both at the transcriptional and post-translational level. p27(Kip1) is a cyclin-dependent kinase inhibitor 1B (CDKN1B) and its mutation or down-regulation can lead to the loss of control over the cell cycle and to the uncontrolled cell proliferation\textsuperscript{113}. Pim-1 may also affect the NF-κB pathway by phosphorylation and stabilization of RelA/p65, an important component of the NF-κB signaling pathway\textsuperscript{112}, and facilitates signaling through the NF-κB pathway by down-regulating the expression of TNFAIP3/A20, a negative inhibitor of NF-κB signaling\textsuperscript{133}. Pim-1 can also phosphorylate P-glycoprotein (MDR-1 gene product), which results in its protection from ubiquitination and proteasomal degradation. Its inhibition reverses resistance to doxorubicin in ovarian cancer cells that overexpress P-glycoprotein\textsuperscript{134}. Experiments that directly link the effects of Pim-1 on NF-κB signaling and increased resistance to cytostatic drugs constitute a valuable and interesting field for further study\textsuperscript{117}.

Carbonic anhydrases (CAs) are metalloenzymes that catalyze the interconversion of carbon dioxide and water to bicarbonate and protons to maintain the acid-base balance in blood and tissues, and to help transport carbon dioxide out of tissues. Hypoxia induces expression of carbonic anhydrase isoform IX (CA IX) via the HIF-1 pathway in many tumors. The role of CA IX in hypoxic tumor acidification processes has been demonstrated\textsuperscript{135}, CA IX decreases extracellular pH, disrupts cellular adhesion by degrading the catenin-cadherin complex or the integrin-mediated cell adhesion system, and induces up-regulation of the genes involved in invasion and migration, and causes resistance to weakly basic cytostatics\textsuperscript{136,137}. An explanation of the changes to the cell adhesion system appears to be linked to acidosis caused by carbonic acid produced by the CA IX-mediated catalytic transformation of carbon dioxide. It is assumed that CA IX inhibition, which normalizes tissue pH, might cause tumor regression.

**METABOLISM, MITOCHONDRIA AND ATP**

The adaptation to hypoxia requires not only the above mentioned changes of expression, but also biochemical responses that counter-balance the decrease in energy supply from mitochondrial respiration. The metabolites influence expression of genes which regulate biochemical pathways that contribute to the metabolic signature of hypoxic cells\textsuperscript{139}. Altered energy metabolism in cancer cells, such as decreased mitochondrial functions and enhanced aerobic glycolysis, is not only a fundamental phenotype of malignant tumors, but also play important roles during tumor progression, metastasis, and relapse\textsuperscript{139,140} and is suspected to contribute to chemoresistance. The precise mechanisms, though, are still unclear\textsuperscript{118}.

It has been shown that the increase in glucose uptake during hypoxia was not reversed by HIF-1α silencing, indicating that bio-energetic needs can also be met by direct biochemical alterations without long-term genetic adaptation\textsuperscript{139}. ATP deprivation occurs in all types of cell death, during late-stage apoptosis, in autophagy, and during necrosis. Therefore, it is suggested that energy metabolism plays a critical role in the survival of cancer cells under stress\textsuperscript{142,143}. Moreover, drug-resistant cells were characterized by defective mitochondrial ATP production, elevated aerobic glycolysis, higher levels of intracellular ATP, and enhanced HIF-1-mediated signaling. Chemoresistant cells need faster ATP generating mechanisms to survive. They consume higher amounts of ATP via the endoplasmic
reticulum enzyme UDPase ENTPD5, which in turn enhances aerobic glycolysis/fermentation\textsuperscript{144}. Under these conditions, HIF-1 acts as a key glycolysis regulator and is up-regulated independently of oxygen levels\textsuperscript{141}. HIF-1 also regulates mitochondrial functions. It has been shown that HIF-1 stabilization under hypoxia leads to the expression of PDK1 (ref.\textsuperscript{145}) protein that phosphorylates and inactivates pyruvate dehydrogenase (PDH), and limits the conversion of pyruvate to acetyl-CoA in the mitochondria. Consequently, PDK1 induction decreases the citric acid cycle (TCA cycle) activity and reduces oxygen consumption\textsuperscript{150}. Intracellular ATP levels are a core determinant in the development of acquired drug resistance of human colon cancer cells that harbor different genetic backgrounds. ATP induced resistance to oxaliplatin and to 5-fluorouracil can be seen in colorectal cancer cells. Conversely, depleting ATP by cell treatment with a glycolysis inhibitor, sensitizes cells resistant to oxaliplatin and also increased sensitivity to 5-fluorouracil\textsuperscript{141}.

It seems that under hypoxia, autophagy is required to support ATP production in addition to glycolysis and its inhibition might be used to selectively target hypoxic regions of tumors. Based on the above mentioned, an understanding of metabolic adaptations under hypoxia could reveal novel pathways that, if targeted, might lead to specific death of hypoxic regions while sparing normal cells that are rarely exposed to hypoxia. Mitochondria are the major oxygen consumers in the cell and are in the heart of several biochemical pathways involved in both energy production and generation of anabolic intermediates that are required for proliferation. Therefore, changes in mitochondrial function under hypoxia are likely to contribute to the altered metabolic profile of cells, making mitochondria important oxygen sensors. They can respire at very low oxygen levels and the rate of respiration of cells adapted to chronic hypoxia demonstrates that they retain active respiration, though at significantly reduced rates. Still, while genetic reprogramming during hypoxia has been characterized and many players in this process have been identified, the contribution of mitochondria to the hypoxic response is remains uncertain\textsuperscript{138}.

**SIDE POPULATION AND CD133**

Cancer stem cell (CSC) models propose that tumors consist of a variety of cells with different proliferative and tumorigenic capacities. According to this theory, small populations of CSC have been suggested as drivers of tumor growth and are responsible for resistance to therapy, recurrence, and metastasis. In hypoxic tumors, CSCs are thought to be regulated by HIF-1α and HIF-2α for survival and protection of tumor growth\textsuperscript{146}. CD133 is one of the most important markers for CSC in a variety of solid tumors. It has been reported in glioma cells that the number of CD133+ cells (CSC) (ref.\textsuperscript{147}) or expression of CD133 in both SCLC and NSCLC cells\textsuperscript{148} was correlated with hypoxia-induced increase of HIF-1α. In pancreatic cancer cells, effects of hypoxia on up-regulation of CD133 was diminished after knocking down HIF-1α (ref.\textsuperscript{149}). Another study suggested that laryngeal cancer cells, subjected to hypoxia followed by normoxia, exhibited enhanced capacities for proliferation, invasion, sphere, and colony formation in comparison with cells which were maintained consistently under normoxia. These events were associated with an increasing CD133+ fraction denoting regulation of cancer stem cells by hypoxic microenvironments\textsuperscript{150}. Moreover, Zhu et al. has demonstrated the role of HIF-1 in intermittent hypoxia on promoting the metastatic ability and invasiveness of CD133+ pancreatic cancer stem-like cells\textsuperscript{151}.

Even though, most of the literature data shows the up-regulation of CD133 during hypoxia, controversy of the regulatory mechanisms of CD133 expression via mTOR signaling and HIF-1α in cancer cells might lead insights into the role of mTOR and oxygen-sensitive intracellular pathways in the maintenance of stemness in CSC (ref.\textsuperscript{152}). It is possible to speculate that in some tumors, one of the mechanisms for hypoxia-induced resistance, may be induction of CSC.

**FUTURE PERSPECTIVES**

Targeting hypoxic cells within solid tumors seems to be a promising treatment modality to overcome resistance and prevent recurrence\textsuperscript{153}. Many different approaches to overcome hypoxia-induced chemo- and/or radioresistance, including inhibitors of HIF-1, or hypoxia, have been developed.

The first clinical studies focused on diagnosis of hypoxia and on the inhibition of hypoxia-induced changes in tumor cells have begun to yield results. Hu et al. have tested (18)F-fluoroerythronitroimidazole PET/CT that uses an assessment of tumor hypoxia to evaluate the prognosis on a group of thirty-two NSCLC patients\textsuperscript{154}. A clinical study examining antisense oligodeoxynucleotide binding HIF-1α showed a decrease in HIF-1 protein levels and mRNA levels in some of its target genes in tumor cells\textsuperscript{155}. Kummer et al. proved that topotecan can decrease expression of HIF-1α and some HIF-1 target genes like VEGF and GLUT-1 in solid tumors\textsuperscript{156}. Other clinical studies have shown that cedeloxib, a selective COX-2 inhibitor, decreased tumor cell proliferation, microvessel density, angiogenesis, HIF-1 levels, and enhanced apoptosis in prostate cancer\textsuperscript{157}. The newly developed prodrug TH-303 (which consist of 2-nitroimidazole covalently linked to brominated isophosphoramid mustard i.e. the prodrug) and which, under hypoxic conditions, is converted into brominated isophosphoramid mustard (i.e. the active cytotoxic drug) seems to be promising. Phase I clinical trials with this drug have already been completed\textsuperscript{158}.

Studies using hyperbaric oxygen therapy (HBOT) with chemotherapy have shown synergistic effects both in vitro and in vivo (for review see ref.\textsuperscript{159}). Moreover, clinical studies in patients with gliomas\textsuperscript{160} and NSCLC (ref.\textsuperscript{161}) have shown promising results, and several studies with the combination of HBOT and radiotherapy have been also performed\textsuperscript{162}. However, this approach is still in its
infancy and a number of questions, e.g. a sequence of individual modalities, duration, and intensity of HBOT need to be resolved.

CONCLUSIONS

In this review we have summarized the most important factors and pathways that contribute to hypoxia-induced chemoresistance in cancer cells. The adaptation to hypoxia requires many genetic and biochemical responses that regulate one another, revealing that hypoxia-induced resistance is a very complex and intricate field about which we still know very little. Since hypoxia is closely associated with chemo- and radioresistance, different approaches are continuously being developed in an effort to circumvent hypoxia-induced resistance.

ABBREVIATIONS

AP-1, Activator protein-1; ARNT, Aryl hydrocarbon receptor nuclear translocator; Bad, Bcl-2-associated death promoter; Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra-large; bHLH-PAS, basic helix-loop-helix - period circadian protein Ah receptor nuclear translocator protein and single-minded protein; BNIP3, Bcl-2/adenovirus E1B 19 kDa interacting protein 3; CA IX, Carbonic anhydrase isoform IX; c-Myc, c-Myc viral oncogene homolog c; COX-2, Cyclooxygenase-2; CDKN1B, Cyclin-dependent kinase inhibitor 1B; EGFR, Epidermal growth factor receptor; EPAS1, Endothelial PAS domain-containing protein 1; Glut-1, Glucose transporter 1; HBOT, Hyperbaric oxygen therapy; HIF-1, Hypoxia-inducible factor-1; HRE, Hypoxia-response element; HSC70, Heat shock cognate protein 70; IAP31, inhibitor of apoptosis 31; c-IAPs, Inhibitors of apoptosis; IκBα, IκBβ, IκBγ, and IκBε, NF-κB inhibitors α, β, γ, and ε; LAMP2A, Lysosome-associated membrane protein 2; MDM2, Mouse double minute 2 homolog; MDR, Multiple drug resistance gene; MRP1, Multidrug resistance protein 1; mTOR, Mammalian target of rapamycin; NF-κB, Nuclear factor-κB; NIX, Nip3-like protein X; NSCLC, Non-small-cell lung cancer; Oct-4, Octamer-binding transcription factor 4; p21/waf1, Cyclin-dependent kinase inhibitor 1; PDK1 and PDK2, Pyruvate dehydrogenase kinases 1 and 2; PDH, Pyruvate dehydrogenase; PET/CT, Positron emission tomography–computed tomography; PHD, Prolyl hydroxylase; PI3K, Phosphoinositol-3-kinase; Pim-1, Pim-2, and Pim-3, Pim serine/threonine kinases 1, 2 and 3; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate; RelA/p65, Nuclear factor NF-kappa-B p65 subunit; S1P, Sphingosine-1-phosphate; SCLC, Small-cell lung cancer; SphK2, Sphingosine kinase 2; STAT3, Signal transducer and activator of transcription 3; TCA cycle, Citric acid cycle; TNFAIP3/A20, Tumor necrosis factor, alpha-induced protein 3; TNF-α, Tumor necrosis factor α; VEGF, Vascular endothelial growth factor; VHL, von Hippel-Lindau protein.

ACKNOWLEDGMENT

Supported by Charles University in Prague, project GA UK No 620612 and by the Ministry of Health of the Czech Republic for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).

Author contributions: JH: wrote the chapters “Hif-1 as a pro- and anti-apoptotic factor” and “Other factors responsible for hypoxia induced chemoresistance”; MAK: wrote the chapter “Side population and CD133”; TE: wrote the chapters “Future perspectives” and “Conclusions” and final revision; HD: wrote all other chapters. All co-authors participated in the conception of the manuscript and revised the whole manuscript.

Conflict of interest statement: The authors state that there are no conflicts of interest regarding the publication of this article.

REFERENCES

roxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther 2009;8:2329-38.


23. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Ninane N, Raes M, Remacle J, Michiels C. Hypoxia induces protec-


26. Gu Y, Moran S, Hogenesch J, Wartman L, Bradfield C. Molecular character-

27. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, Yeung SC, Lee MH. Pim-1 plays a vital role in hypoxia-induced chemoresis-


35. Yang Y, Karakhanova S, Werner J, Bazhin A V. Reactive oxygen spe-

36. Miyata T, Takizawa S, van Ypersele de Strihou C. Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel thera-

37. Hubbi ME, Hu H, Khitiz, Ahmed I, Lavenko A, Semenza GL. Chaperone-mediated autophagy targets hypoxia-inducible factor-


39. Hung MC, Mills GB, Yu D. Oxygen sensor boosts growth factor signal-


43. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Ninane N, Raes M, Remacle J, Michiels C. Hypoxia induces protec-


45. Liu XW, Su Y, Zhu H, Cao J, Ding WJ, Zhao YC, Chen J, Li J, Yang B. HIF-1α-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-


47. Robert DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-


50. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Ninane N, Raes M, Remacle J, Michiels C. Hypoxia induces protec-


144. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, Wang X. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010;143:711-24


